We are international

Recently in Robin Tuohy Category

Day One at #ASH13

| No Comments | No TrackBacks

Hi Everyone!

Every day my blog posts will start "This was the best day!"  Because every day at the annual meeting of the American Society of Hematology (ASH) is full of hope for myeloma patients!  Hope for our futures, for new treatments, better quality of life, longer overall survival, and fewer side effects.  If you want a shot of hope, read my blogs and follow me on Twitter:  @IMFsupport.

"Today was the best day!"  Today, thanks to the IMF, we heard some of the top myeloma experts weigh in and give the "yes" side and the "no" side of various debates.  The title of today's program was:  Critical Issues Need Answers:

Providing Best Options for Myeloma Treatment in 2013

Symposium Topics Are:

  • Initiate Therapy for High-Risk Smoldering Myeloma--Yes or No?
  • Early Transplantation in Multiple Myeloma--Yes or No?
  • Melphalan as Part of Induction Therapy for the Elderly Patient--Yes or No?
  • Maintenance Therapy--Yes or No?
  • Early Integration of New Therapies in the Salvage Setting--Yes or No?


Speaker 1: Brian G.M. Durie, MD 

Institution: Cedars-Sinai Outpatient Cancer Center, Los Angeles, California 

Speaker 2: Shaji Kumar, MD

Institution: Mayo Clinic, Rochester, MN 

Speaker 3: Jesús F. San-Miguel MD, PhD 

Institution: University of Salamanca, Salamanca, Spain 

Speaker 4: Philippe Moreau, MD 

Institution: University Hospital Hôtel-Dieu, Nantes, France 

Speaker 5: Antonio Palumbo, MD 

Institution: University of Turin, Turin, Italy 

Speaker 6: S. Vincent Rajkumar, MD 

Institution: Mayo Clinic College of Medicine, Rochester, Minnesota

Quite a lineup of myeloma experts!

You can view the speaker slides here:  


The IMF had to bring in extra chairs for this session and we were at fire code maximum!  That means more hematologists/oncologists learning the latest about how to treat myeloma!  Excellent myeloma awareness and excellent for myeloma patients!  Here's a pix of the "at capacity" room:

Dr. Rajkumar said:  Myeloma is not one disease, one size does not fit all regarding treatment.  I love that we are treating the patient as a person and not the disease!  This is critical for long term survival! Thank you Dr. Rakjumar!

High Dose Treatment helps some patients, but we do not know who benefits the most.

As the programs at ASH continue over the next few days, please check out all the patients' blogs (written, video) and Tweets.  For details, please follow our social media team at:


That's it for tonight, hope you enjoyed your dose of hope!

-- Robin Tuohy

The IMF at ASH 2013

All Blogs

IMF Articles